D-0361-2025 Class II Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0361-2025 was initiated by Zydus Pharmaceuticals (USA) Inc on Apr 3, 2025 and is designated Class II. Reason for recall: CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit The recall status is ongoing. Affected quantity: 3144 bottles, pack size: 100's Count.

Recall details

Product Type
Drugs
Report Date
Apr 16, 2025
Initiation Date
Apr 3, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3144 bottles, pack size: 100's Count

Product description

chlorproMAZINE Hydrochloride Tablets, USP 10 mg, Rx Only, 100 Tablets bottles, Manufactured by: Zydus Lifesciences Ltd., Baddi, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1129-1

Reason for recall

CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit

Distribution pattern

Nationwide within U.S - MS, AL, TN, VT, OH, ND, MN, WI, SC, AR, FL, IN, LA, NJ, AZ, TX, KY and PA

Code information

Lot #: Z400069, Exp.: 12/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0361-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0361-2025. Report a data issue: hello@regdatalab.com.